Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IdorsiaXSWX:IDIA -4.33%49 3-Year EPS without NRI Growth Rate is 45.40% as of Jun. 2026. GuruFocus rates XSWX:IDIA with a GF Score™ of 49/100 and a GF Value™ of CHF2.32 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,161 Biotechnology companies, Idorsia ranks better than 81.4% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 45.40% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 22.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 10 years, the highest 3-Year average EPS without NRI Growth Rate of Idorsia was 45.40% per year. The lowest was -9.00% per year. And the median was -5.25% per year.
Idorsia (XSWX:IDIA) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Idorsia 3-Year EPS without NRI Growth Rate Related Terms
XSWX:IDIA vs VRTX, REGN, RVMD: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Idorsia's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Idorsia 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Idorsia's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Idorsia's 3-Year EPS without NRI Growth Rate falls into.
Idorsia 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 45.40% mean?
Idorsia (XSWX:IDIA) has a 3-Year EPS without NRI Growth Rate of 45.40% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Idorsia and its competitors. According to the industry distribution chart, Idorsia ranks #216 out of 1161 companies in the Biotechnology industry, placing it in the top 18.6%.
Is Idorsia's 3-Year EPS without NRI Growth Rate too high?
Idorsia's current 3-Year EPS without NRI Growth Rate is 45.40%. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.20. Idorsia's value of 45.40% is 180.2% above this industry median. Based on the distribution chart, Idorsia ranks #216 out of 1161 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Idorsia has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Idorsia's 3-Year EPS without NRI Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Idorsia ranks #216 out of 1161 companies for 3-Year EPS without NRI Growth Rate. This places Idorsia in the top 19% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 16.20. Idorsia's value of 45.40% is 180.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.20, based on 1,161 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Idorsia's current 3-Year EPS without NRI Growth Rate of 45.40% is 180.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Idorsia and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Idorsia's current 3-Year EPS without NRI Growth Rate is 45.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Idorsia stock overvalued right now?
Based on GuruFocus' analysis, Idorsia (XSWX:IDIA) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF2.32, compared to a current price of CHF5.63 — trading 142.7% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 45.40% and 180.2% above the Biotechnology industry median of 16.20. Idorsia's overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Idorsia (XSWX:IDIA), the current 3-Year EPS without NRI Growth Rate is 45.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Idorsia (XSWX:IDIA) Overvalued in 2026?
Based on GuruFocus' analysis, Idorsia stock appears to be overvalued.
The current stock price of CHF5.63 is trading 142.7% above its estimated GF Value™ of CHF2.32.
GuruFocus considers Idorsia to be Significantly Overvalued.
Key valuation signals for XSWX:IDIA:
3-Year EPS without NRI Growth Rate: 45.40%
GF Value™: CHF2.32 vs. price of CHF5.63 (142.7% above fair value)
Industry Position: 180.2% above the Biotechnology median (#216 of 1161)
No single metric tells the full story. See the XSWX:IDIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. The company is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. The company's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.
49GF Score
Get the complete analysis for XSWX:IDIA
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:IDIA has been successfully added to your 
